Anti-Erythropoietin Antibodies and Pure Red Cell Aplasia

Journal of the American Society of Nephrology

Volumn 15, Issue 2, 2004, Pages 398-406

  Rossert, Jerome ^a   Casadevall, Nicole ^b   Eckardt, Kai Uwe ^c,d  

^a HÔPITAL TENON   (France)

^b HÔTEL DIEU   (France)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; POLYCLONAL ANTIBODY; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; BONE MARROW BIOPSY; DIAGNOSTIC VALUE; DISEASE SEVERITY; HUMAN; IMMUNIZATION; KIDNEY DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REVIEW;

EID: 0942287103     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000107561.59698.42     Document Type: Review

References (36)

1. Garcia JF, Clemmons G: The radioimmunoassay of erythropoietin. In: Recent Advances in Nuclear Medicine, Vol. VI, edited by Lawrence JH, New York, Grune & Stratton, 1983: 19-40.
2. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 339: 578-83, 1998
3. Anonymous: NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37[Suppl 1]: S182-S238, 2001
4. Anonymous: European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure Guideline 9: Route of administration of epoctin. Nephrol Dial Transplant 14[Suppl 5]: 19-20, 1999
5. Bergrem H, Danielson BG, Eckardt K-U, Kurtz A, Stridsberg M: A case of anti-erythropoietin antibodies following recombinant human erythropoietin treatment. In: Erythropoietin: Molecular Physiology and Clinical Application, edited by Bauer C, Koch KM, Scigalla P, New York, Marcel Dekker, 1993, pp 266-275
6. Peces R, de la Torre M, Alcazar R, Urra JM: Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 335: 523-524, 1996
7. Prabhakar SS, Muhlfelder T: Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 47: 331-335, 1997
8. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P: Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469-475, 2002
9. Eckardt KU, Casadevall N: Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 18: 865-869, 2003
10. Gershon SK, Luksenburg H, Cote TR, Braun MM: Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 346: 469-475, 2002
11. Krantz SB: Pure red-cell aplasia. N Engl J Med 291: 345-350, 1974
12. th ed., edited by Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, New York, McGraw-Hill, 2000, pp 391-398
13. Peschle C, Mannont AM, Marone G, Genovese A, Sasso GF, Condorelli M: Pure red cell aplasia: Studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol 30: 411-417, 1975
14. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P: Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 334: 630-633, 1996
15. Linardaki GD, Boki KA, Fertakis A, Tzioufas AG: Pure red cell aplasia as presentation of systemic lupus erythematosus: Antibodies to erythropoietin. Scand J Rheumatol 28: 189-191, 1999
16. Geetha D, Zachary JB, Baldado HM, Kronz JD, Kraus ES: Pure red cell aplasia caused by Parvovirus B 19 infection in solid organ transplant recipients: A case report and review of literature. Clin Transplant 14: 586-591, 2000
17. Brown KE, Young NS: Parvovirus B19 in human disease. Annu Rev Med 48: 59-67, 1997
18. Verhelst D, Rossert J, Casadevall N, MacDougall IC, Kruger A, Eckardt KU: Treatment of antibody-mediated pure red cell aplasia. J Am Soc Nephrol 14: 27A, 2003
19. Cavill I, Williams JD: Benefits of recombinant human erythropoietin. Lancet 360: 1606-1607, 2002
20. Ishibashi T, Koziol JA, Burstein SA: Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J Clin Invest 79: 286-289, 1987
21. Fraser JK, Tan AS, Lin FK, Berridge MV: Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp Hematol 17: 10-16, 1989
22. Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU: Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 13: 2381-2383, 2002
23. Wu G, Nathoo B, Mendelssohn D, Pandeya S: Antibody to erythropoietin in surveillance study in 5 Ontario renal centers. Nephrol Dial Transplant 18[Suppl 4]: 162, 2003
24. Van Regenmorte: Improving the quality of BIACORE-based affinity measurements. Dev Biol 112: 141-151, 2003.
25. Mason S, La S, Mytych D, Swanson SJ, Ferbas J: Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Curr Med Res Opin 7: 651-659, 2003
26. Netti GS, Petruzzelli V, Blasi A, Roca L, Ranieri E, Di Paolo S, Pertosa G, Grandaliano G, Schena FP, Gesualdo L: May recombinant erythropoietin induce a specific T-cell-mediated immune response. Nephrol Dial Transplant 18[Suppl 4]: 161, 2003
27. Reding MT, Wu H, Krampf M, Okita DK, Diethelm-Okita BM, Christie BA, Key NS, Conti-Fine BM: Sensitization of CD4+ T cells to coagulation factor VIII: Response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 84: 643-652, 2000
28. Hay CR, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, Colvin BT, Hill FG, Preston FE, Peake IR: HLA class II profile: A weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 77: 234-237, 1997
29. http://www.jnj.com/news/jnj_news/1021024_095632.htm?textOnly=false. Accessed November, 2003.
30. Schellekens H: Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1: 457-462, 2002
31. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, Lee J: Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 100: 79-89, 1998
32. Skibeli V, Nissen-Lie G, Torjesen P: Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 98: 3626-3634, 2001
33. Hermeling S, Schellekens H, Daan J: A, Crommelin, Jiskoot W: Micelle-associated protein in epoetin formulations: A risk factor for immunogenicity? Pharm Res 20: 1903-1908, 2003
34. Bachmann MF, Hoffmann RU, Kündig TM, Bürki K, Hengartner H, Zinkernagel RM: The influence of antigen organization on B cell responsiveness. Science 262: 1448-1451, 1993
35. Chng WJ, Tan LK, Liu TC: Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapy. Am J Kidney Dis 41: 692-695, 2003
36. Louet S: Lessons from Eprex for biogeneric firms. Nat Biotechnol 21: 956-957, 2003